Patients with immune-related adverse events (irAEs) during pretransplant immune checkpoint inhibitor (ICI) therapy had a markedly higher odds of post‑transplant liver allograft rejection (OR 9.17).
A short washout period from last ICI dose to transplantation (<30 days) and recipient age under 40 years were additional independent risk factors; a multivariable model showed acceptable discrimination (AUC 0.788).
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
